Sunday 18 October 2026
Export FHTX’s income statement to Excel — free account
Foghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.
1.85
0.04
−2.12%
Follow FHTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 2 | 3 |
+8 more TTM periods Free account |
| 81.90% | 109.12% | 96.45% | 122.30% | ||
| (30.06%) | (31.33%) | (30.82%) | (28.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(53.39%) | (60.08%) | (70.47%) | (66.97%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.19) | (1.26) | (1.37) | (1.41) | |
Free Cash Flow |
(84.31) | (87.40) | (86.15) | (88.88) | |
Capital Expenditures |
(0.07) | — | (0.05) | (0.53) | |
| Other line items | |||||
Cash ROIC |
(97.43%) | (80.57%) | (166.81%) | (96.74%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
214.57% | 290.88% | 276.51% | 342.31% | |
Selling, General and Administrative Expense of Revenue |
71.81% | 95.28% | 89.13% | 110.56% | |
Share Based Compensation of Revenue |
26.97% | 35.75% | 33.64% | 43.40% | |
Operating CF/Net income |
1.30 | 1.16 | 1.16 | 1.23 | |
Depreciation/Fixed assets |
0.30 | 0.73 | 0.73 | 0.01 | |
Capex/Depreciation |
(0.16) | 0.00 | (0.04) | (5.19) | |
Revenue per Share |
0.52 | 0.41 | 0.49 | 0.39 | |
Operating CF per Share |
(1.19) | (1.26) | (1.37) | (1.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 |
Columns are period end dates